BidaskClub Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold

Share on StockTwits

BidaskClub downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research note released on Saturday, BidAskClub reports.

A number of other analysts have also commented on ALNY. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $126.00 to $124.00 and set an overweight rating on the stock in a report on Wednesday, August 7th. Barclays reissued a buy rating and issued a $125.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. UBS Group upped their price objective on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a neutral rating in a research note on Wednesday, September 4th. ValuEngine raised Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Finally, Goldman Sachs Group reaffirmed a neutral rating and set a $80.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 23rd. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of Buy and an average target price of $116.13.

NASDAQ:ALNY opened at $84.27 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. The firm has a market cap of $8.88 billion, a price-to-earnings ratio of -11.13 and a beta of 2.35. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $103.50. The firm has a 50-day moving average price of $79.52 and a two-hundred day moving average price of $78.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.06) by $0.04. The firm had revenue of $38.20 million for the quarter, compared to analysts’ expectations of $42.24 million. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.61) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -8.21 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in Alnylam Pharmaceuticals by 41.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 225,148 shares of the biopharmaceutical company’s stock worth $16,412,000 after buying an additional 66,253 shares during the last quarter. Geode Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 915,533 shares of the biopharmaceutical company’s stock valued at $66,708,000 after acquiring an additional 34,770 shares during the period. Quadrant Capital Group LLC lifted its holdings in Alnylam Pharmaceuticals by 543.2% during the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 440 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Alnylam Pharmaceuticals by 3.4% during the first quarter. Janus Henderson Group PLC now owns 25,243 shares of the biopharmaceutical company’s stock valued at $2,360,000 after purchasing an additional 841 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Alnylam Pharmaceuticals by 2.5% during the first quarter. Rhumbline Advisers now owns 92,891 shares of the biopharmaceutical company’s stock valued at $8,681,000 after purchasing an additional 2,295 shares during the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: Initial Coin Offering (ICO)

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.